Meta-analysis of 9 observational studies of intranasal esketamine in treatment-resistant depression: large symptom reduction (Hedges' g -1.98) and higher remission odds at 3 months than at induction (OR 5.1); 82% had any adverse event, 49% dissociation. No control groups.
Meta-analysisn = 9 studies
de Oliveira Lapa et al. Systematic review and meta-analysis of intranasal esketamine for treatment-resistant depression: Evidence from real-world studies